Biologics are genetically-engineered proteins derived from human and/or
animal genes. The use of biologics has significantly changed the management of rheumatoid
arthritis over the last decade, becoming the cornerstone treatment for
many patients.
Because the arsenal of biologics for rheumatoid arthritis
includes numerous monoclonal antibodies with various mechanisms of
action, it can be challenging to optimize treatments for individuals.
Aperion Biologics' New Treatment Method Promotes Xenographic ACL Transplants
New method for porcine ACL tissue will prevent the tissue from triggering a rejection response, without disrupting its ligament structure and mechanical properties.
Advertisement
‘Blood concentrations of biologics can vary from patient to patient and may correlate with therapeutic response. Therefore, the use of a 'one dose fits all' approach needs to be reassessed.’
Tweet it Now
A new review of the medical literature indicates that blood concentrations of biologics can vary from patient to patient and may correlate with therapeutic response. Therefore, the use of a 'one dose fits all' approach, mainly proposed by pharmaceutical companies, needs to be reassessed. In general, individualized doses of biologics should be implemented in clinical practice.
"Since their usage is spreading, the study of factors and covariates
that could relevantly influence serum drug concentrations and exposure
would be extremely useful to better understand and predict drugs'
pharmacokinetic/pharmacodynamic behavior in advance," wrote the authors
of the British Journal of Clinical Pharmacology review.
"Moreover, the applicability of population pharmacokinetic and pharmacodynamic models in the clinical setting would allow us to select the suitable dose for specific patients at the same time a cost-efficient approach is considered."
Source: Eurekalert
"Moreover, the applicability of population pharmacokinetic and pharmacodynamic models in the clinical setting would allow us to select the suitable dose for specific patients at the same time a cost-efficient approach is considered."
Source: Eurekalert
A More Powerful Way to Develop New 'Biologics': University of Toronto
A new method for identifying the raw ingredients necessary to build 'biologics' has been developed by a University of Toronto researcher.
Advertisement
 Inequalities in Access to Biologics for Treatment of ArthritisA recent study has outlined the huge inequalities in access to biologics for the treatments of rheumatoid arthritis (RA) across 46 European countries. | Advertisement
|
In People Taking Biologics for Autoimmune Diseases, Vaccine Does Not Increase Shingles Risk
New research says that a live attenuated shingles vaccine called Zostavax® does not appear to increase the short-term risk of developing shingles infection
Advertisement
